Literature DB >> 16304089

Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma.

Yoshiki Asayama1, Kengo Yoshimitsu, Hiroyuki Irie, Tsuyoshi Tajima, Akihiro Nishie, Masakazu Hirakawa, Tomohiro Nakayama, Daisuke Kakihara, Akinobu Taketomi, Shin-ichi Aishima, Hiroshi Honda.   

Abstract

PURPOSE: To retrospectively determine whether the degree of contrast material enhancement at delayed-phase dynamic computed tomography (CT) for intrahepatic cholangiocarcinoma (ICC) is related to the patient's prognosis after surgery.
MATERIALS AND METHODS: Neither institutional review board approval nor informed consent was required for this retrospective evaluation. Thirty-two patients (22 men, 10 women; mean age, 60.8 years; range, 33-80 years) with mass-forming ICC underwent dynamic CT. Delayed CT images obtained 4-6 minutes after the injection of contrast material were evaluated by two radiologists. Patients were classified in consensus into one of two groups: Group 1 included those in whom more than two-thirds of the tumor showed enhancement on delayed-phase scans. Group 2 included those in whom less than two-thirds of the tumor showed enhancement on delayed-phase scans. The imaging findings were correlated with pathologic findings. Survival curves were drawn by using the Kaplan-Meier method, and the differences between the groups were compared with the log-rank test. Multivariate analysis was performed to clarify prognostic factors.
RESULTS: There were 13 patients in group 1 and 19 in group 2. The degree of enhancement on the delayed-phase images showed statistically significant correlation with the amount of fibrous stroma (P < .001) and the frequency of perineural invasion (P < .01). The survival rate in group 1 was significantly lower than that in group 2 (P = .016). Multivariate analysis revealed that enhancement of more than two-thirds of the ICC was a significant and independent prognostic factor.
CONCLUSION: The degree of enhancement on delayed-phase CT scans is a useful indicator for prediction of the prognosis of patients with mass-forming ICC. RSNA, 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304089     DOI: 10.1148/radiol.2381041765

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  31 in total

1.  Value of two-phase dynamic multidetector computed tomography in differential diagnosis of post-inflammatory strictures from esophageal cancer.

Authors:  Grigory G Karmazanovsky; Svetlana A Buryakina; Evgeny V Kondratiev; Qin Yang; Dmitry V Ruchkin; Dmitry V Kalinin
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

Review 2.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

3.  Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings.

Authors:  Nobuhiro Fujita; Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Huanlin Wang; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-05-10       Impact factor: 5.315

4.  Intrahepatic mass-forming cholangiocarcinoma: prognostic value of preoperative gadoxetic acid-enhanced MRI.

Authors:  Jieun Koh; Yong Eun Chung; Ji Hae Nahm; Ha Yan Kim; Kyung-Sik Kim; Young Nyun Park; Myeong-Jin Kim; Jin-Young Choi
Journal:  Eur Radiol       Date:  2015-05-23       Impact factor: 5.315

5.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

6.  Distinguishing intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma using precontrast and gadoxetic acid-enhanced MRI.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Nobuhiro Fujita; Yuichiro Kubo; Shinichi Aishima; Ken Shirabe; Takashi Yoshiura; Hiroshi Honda
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

Review 7.  Imaging of Cholangiocarcinoma.

Authors:  Susann-Cathrin Olthof; Ahmed Othman; Stephan Clasen; Christina Schraml; Konstantin Nikolaou; Malte Bongers
Journal:  Visc Med       Date:  2016-12-06

Review 8.  Multimodality imaging of intrahepatic cholangiocarcinoma.

Authors:  Kelly Fábrega-Foster; Mounes Aliyari Ghasabeh; Timothy M Pawlik; Ihab R Kamel
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

9.  Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Nobuhiro Fujita; Takao Ohtsuka; Tomoharu Yoshizumi; Shinichi Aishima; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

10.  Contrast-enhanced ultrasound appearances of enhancement patterns of intrahepatic cholangiocarcinoma: correlation with pathological findings.

Authors:  Francesco Loria; Giuseppe Loria; Salvatore Basile; Giuseppe Crea; Luciano Frosina; Isidoro Di Carlo
Journal:  Updates Surg       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.